Quality control method for the noninvasive screening of biochemical indicators during early pregnancy

A technology of biochemical indicators and quality control methods, applied in biological testing, material inspection products, special data processing applications, etc., can solve the problem of no quality control system for serum parameters, and achieve the effect of optimizing accuracy and improving detection rate

Inactive Publication Date: 2009-09-16
广州医学院
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, most of the known screenings in China use individual serum parameters for risk assessment, and there is no relevant content about the quality control system of serum parameters

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quality control method for the noninvasive screening of biochemical indicators during early pregnancy
  • Quality control method for the noninvasive screening of biochemical indicators during early pregnancy
  • Quality control method for the noninvasive screening of biochemical indicators during early pregnancy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] 1. Determination of biochemical indicators in noninvasive screening of birth defects in the first trimester

[0018] In the non-invasive screening of birth defects in the first trimester, the maternal serum biochemical indicators are free β-hCG and PAPP-A, among which,

[0019] PAPP-A: pregnancy-associated plasma protein A, which is mainly a macromolecular glycoprotein produced by the placenta and decidua. During pregnancy, the concentration of PAPP-A in maternal blood increases with the increase of pregnancy, but at 21-3 In patients with trisomy 18 and 13, the concentration of PAPP-A in maternal blood was significantly lower, and the mean value of MoM was about 0.4.

[0020] Free β-hCG: Chorionic gonadotropin β subunit, in normal pregnancy, the level of free β-hCG in maternal blood decreases with gestational age, while in trisomy 21, the concentration of free β-hCG increases significantly, MoM The mean value is above 2.0.

[0021] The unit of measurement used in pren...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a quality control method established specially for invasive screening of biochemical indicators during early pregnancy. The method includes the steps of: determining a proper maternal serum biochemical indicator through a preposing maternal serum biochemical detection program according to a selected pregnancy period; obtaining a detection value of the maternal serum biochemical indicator input into a computer and the background parameters of a checked pregnant woman; reading the detection value of the maternal serum biochemical indicator and a corrected MoM value and plotting the values on a preset maternal serum indicator distribution model diagram of normal pregnancy cohort; forming an MoM distribution diagram and a Log10 (MoM) distribution diagram of the maternal serum biochemical indicator of a checked cohort and establishing a normal distribution model of the maternal serum biochemical indicator of the checked cohort; and taking the model as a quality control standard to conduct quality control. The method can aim at a certain range of checked cohorts to carry out the quality control on the invasive screening of the biochemical indicators during early pregnancy, optimize the accuracy of a screening evaluation system and improve the detectable rate of the screening.

Description

technical field [0001] The invention belongs to the field of medical clinical diagnosis, and relates to a quality control method specially established for non-invasive biochemical index screening in the first trimester. Background technique [0002] Prenatal screening is a simple, economical and less invasive detection method to find certain high-risk pregnant women suspected of having congenital defects and genetic diseases from among pregnant women, so as to further confirm the diagnosis. The non-invasive screening method for birth defects in the first trimester refers to the risk value of chromosomal abnormal birth defects calculated by combining the background risk of pregnant women in the first trimester, the risk of ultrasound index examination, the risk of maternal serum biochemical detection and other factors. This method involves the establishment of a large number of mathematical models and complex data calculations, and requires professional risk assessment and sc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/74G01N33/68G06F19/00
Inventor 孙筱放周大海
Owner 广州医学院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap